April 4 (Reuters) - Sonnet Biotherapeutics Holdings Inc SONN.O:
SONNET’S SON-1010 DEMONSTRATES A STRONG SAFETY PROFILE IN COMBINATION WITH ATEZOLIZUMAB FOR TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER, INCLUDING A PARTIAL RESPONSE AT THE HIGHEST DOSE
SONNET BIOTHERAPEUTICS HOLDINGS INC - TOPLINE SAFETY DATA SUGGEST CLINICAL BENEFIT OF SON-1010 WITH ATEZOLIZUMAB
Source text: ID:nGNX6KdhK7
Further company coverage: SONN.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.